FibroGen, Inc. — 2016 Form 10-K Summary
Entity note: The request metadata names Kyntra Bio, Inc., but the supplied filing is FibroGen, Inc. This summary reflects the filing. It covers the fiscal year ended December 31, 2016; the fourth quarter ended December 31, 2016.
Business context
FibroGen is a clinical-stage biopharmaceutical company with no approved products and no product-sales revenue. Its lead candidate, roxadustat, was in Phase 3 development for anemia in chronic kidney disease (CKD), with Astellas and AstraZeneca as partners. Pamrevlumab was in Phase 2 development for idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD). The company also had a corneal implant candidate in preclinical development.
Financial performance and liquidity
| Metric | FY 2016 | FY 2015 | 4Q 2016 | 4Q 2015 |
|---|---|---|---|---|
| Revenue | $179.6 million | $180.8 million | $31.9 million | $24.4 million |
| Operating expenses | $233.2 million | $258.5 million | $63.2 million | $72.9 million |
| Operating loss | $53.7 million | $77.6 million | Not separately stated for the quarter | Not separately stated for the quarter |
| Net loss | $61.7 million | $85.8 million | $34.0 million | $51.4 million |
| Net loss per share, diluted | $0.98 | $1.42 | $0.54 | $0.83 |
Annual revenue was almost entirely from collaboration agreements, chiefly roxadustat-related license, milestone, and development-service revenue. The filing reports no product sales or product gross margin. Revenue and quarterly results are affected by the timing and accounting recognition of partner payments.
Research and development expense was $187.2 million in 2016, down from $214.1 million; general and administrative expense was $46.0 million, up from $44.4 million. Stock-based compensation totaled $32.1 million, versus $27.7 million in 2015.
Cash and cash equivalents were $173.8 million; short- and long-term investments totaled $150.4 million. Together with $10.4 million of receivables, these resources totaled $334.6 million. Working capital was $201.4 million. Operating activities provided $7.1 million of cash in 2016, compared with $18.6 million used in 2015; cash and cash equivalents increased $20.5 million during 2016. Management said available resources were expected to fund operations for at least 12 months from the filing’s reporting date, while warning that estimates and funding needs could change.
Reported obligations included $97.9 million of lease financing obligations and $14.9 million of product-development obligations. The latter were TEKES advances; repayment depends on FibroGen Europe having distributable funds, and loans may be forgiven under specified conditions. The filing does not present these amounts as conventional funded borrowings.
Material changes and notable items
- Revenue decreased $1.3 million, or 1%, year over year. Lower AstraZeneca license and milestone revenue, including smaller 2016 partner payments than in 2015, was largely offset by higher collaboration-service revenue.
- Operating expenses declined $25.2 million, or 10%, primarily because FibroGen reached its $116.5 million cap on its share of certain roxadustat development costs in late 2015. In 2016, partners covered the applicable non-China development costs; clinical trial spending nevertheless increased.
- Net loss narrowed by $24.1 million year over year, principally reflecting lower operating expenses. The $24.3 million net income reported in 2Q 2016 followed the recognition of significant collaboration-related revenue; it did not represent recurring product-sales profitability.
- Operating cash flow improved from use of $18.6 million to generation of $7.1 million. Deferred revenue and receivables timing under collaboration contracts were important working-capital factors.
- Revenue concentration remained high: AstraZeneca accounted for 86% of 2016 revenue and Astellas 14%. The partners also represented 61% and 39%, respectively, of year-end accounts receivable.
Outlook, management commentary, and risks
- Management anticipated filing a U.S. roxadustat NDA in 2018 and planned a China filing in 3Q 2017, subject to completing the ongoing safety extension. China Phase 3 topline results reported in the filing met primary efficacy endpoints in both non-dialysis and dialysis CKD studies; longer-term safety assessment and full results remained pending.
- Management expected topline results from the randomized Phase 2 IPF study in 3Q 2017, and expected to complete the pancreatic cancer study’s treatment period by year-end 2017. These are forward-looking expectations, not guarantees.
- FibroGen continued to incur losses and expected significant research and development spending for years. It may need additional financing if development costs, timing, partnerships, or commercialization plans change.
- Roxadustat’s approval depends on extensive Phase 3 evidence, including cardiovascular safety endpoints. Phase 2 results may not predict Phase 3 outcomes; the filing also discusses possible statin interactions and the potential for previously unobserved safety risks.
- Other material risks include dependence on Astellas and AstraZeneca, trial enrollment and execution, manufacturing capacity and third-party suppliers, regulatory approval and reimbursement, competition from ESAs and other HIF-PH inhibitors, and China-specific regulatory, manufacturing, pricing, currency, and intellectual-property risks.
- Revenue accounting is subject to significant judgments. FibroGen planned to adopt the new revenue standard in 1Q 2018 using full retrospective application and expected that milestone revenue recognition could be deferred under the new standard; the precise impact had not been finalized.
- The independent auditor gave an unqualified opinion on the financial statements and internal control over financial reporting. Management also concluded disclosure controls and internal controls were effective as of December 31, 2016. FibroGen reported no material legal proceedings.
Important facts for investors to verify
- Whether roxadustat’s Phase 3 results support safety and efficacy claims, particularly cardiovascular non-inferiority, and whether the anticipated U.S. and China filing timelines remain achievable.
- Completion and results of the China safety extension, and whether regulatory authorities require additional studies or impose limitations on approval or labeling.
- Cash use, collaboration reimbursements and milestone timing, and whether the stated 12-month liquidity outlook remains adequate as programs advance.
- How the new revenue standard changes reported collaboration revenue, deferred revenue, and historical comparisons.
- Partner concentration and the effect of any collaboration termination, change in partner priorities, or dispute on development funding and commercialization.
- Progress on commercial manufacturing readiness in China and securing reliable commercial supply elsewhere, including resolution of the disclosed IRIX manufacturing-rights issue.